| 0 |
LYSINURIC PROTEIN INTOLERANCE |
1 |
0.5000 |
| 1 |
INTERFERON GAMMA DECREASED |
1 |
0.1111 |
| 2 |
NATURAL KILLER T CELL COUNT INCREASED |
1 |
0.0909 |
| 3 |
ERYTHROBLASTOSIS |
2 |
0.0400 |
| 4 |
CHEMOKINE INCREASED |
1 |
0.0370 |
| 5 |
FAMILIAL HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS |
1 |
0.0323 |
| 6 |
ABNORMAL ORGAN GROWTH |
1 |
0.0227 |
| 7 |
CYTOKINE ABNORMAL |
1 |
0.0192 |
| 8 |
BLOOD FIBRINOGEN ABNORMAL |
1 |
0.0175 |
| 9 |
HYPERRESPONSIVE TO STIMULI |
1 |
0.0159 |
| 10 |
HEPATOBLASTOMA |
1 |
0.0103 |
| 11 |
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS |
72 |
0.0096 |
| 12 |
AUTOINFLAMMATORY DISEASE |
2 |
0.0094 |
| 13 |
NUCLEATED RED CELLS |
1 |
0.0089 |
| 14 |
ALVEOLAR PROTEINOSIS |
5 |
0.0084 |
| 15 |
HYPERFERRITINAEMIA |
3 |
0.0070 |
| 16 |
SERUM FERRITIN ABNORMAL |
2 |
0.0063 |
| 17 |
CYTOMEGALOVIRUS SYNDROME |
1 |
0.0061 |
| 18 |
GLYCOSURIA |
8 |
0.0059 |
| 19 |
MEASLES |
3 |
0.0056 |
| 20 |
GRANULOCYTOSIS |
1 |
0.0051 |
| 21 |
CD4 LYMPHOCYTES ABNORMAL |
1 |
0.0048 |
| 22 |
BONE MARROW TRANSPLANT REJECTION |
1 |
0.0045 |
| 23 |
DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION |
1 |
0.0045 |
| 24 |
ADENOVIRUS INFECTION |
13 |
0.0045 |
| 25 |
HUMAN HERPESVIRUS 6 ENCEPHALITIS |
1 |
0.0035 |
| 26 |
STREPTOCOCCAL SEPSIS |
4 |
0.0034 |
| 27 |
TEETHING |
1 |
0.0033 |
| 28 |
HYPOFIBRINOGENAEMIA |
3 |
0.0030 |
| 29 |
ENTEROCOCCAL BACTERAEMIA |
3 |
0.0028 |
| 30 |
HERPES ZOSTER MENINGOENCEPHALITIS |
1 |
0.0028 |
| 31 |
PRODUCT SELECTION ERROR |
3 |
0.0027 |
| 32 |
ANISOCORIA |
1 |
0.0026 |
| 33 |
T-CELL LYMPHOMA |
3 |
0.0026 |
| 34 |
BLOOD FIBRINOGEN INCREASED |
2 |
0.0025 |
| 35 |
ENTEROBACTER INFECTION |
4 |
0.0024 |
| 36 |
SERUM FERRITIN INCREASED |
12 |
0.0023 |
| 37 |
EPSTEIN-BARR VIRUS INFECTION |
14 |
0.0022 |
| 38 |
PNEUMONIA CYTOMEGALOVIRAL |
4 |
0.0021 |
| 39 |
EPIGLOTTITIS |
1 |
0.0018 |
| 40 |
INTERLEUKIN LEVEL INCREASED |
1 |
0.0018 |
| 41 |
SERUM FERRITIN DECREASED |
3 |
0.0017 |
| 42 |
MONOCYTE COUNT DECREASED |
2 |
0.0016 |
| 43 |
BLOOD IMMUNOGLOBULIN A DECREASED |
1 |
0.0015 |
| 44 |
VIRAEMIA |
2 |
0.0014 |
| 45 |
ESCHERICHIA SEPSIS |
4 |
0.0014 |
| 46 |
BRAIN DEATH |
4 |
0.0013 |
| 47 |
HERPES ZOSTER DISSEMINATED |
1 |
0.0012 |
| 48 |
BACTERIAL SEPSIS |
4 |
0.0012 |
| 49 |
BLOOD TRIGLYCERIDES ABNORMAL |
1 |
0.0011 |
| 50 |
CYTOMEGALOVIRUS TEST POSITIVE |
2 |
0.0011 |
| 51 |
BLOOD IMMUNOGLOBULIN M DECREASED |
1 |
0.0010 |
| 52 |
VARICELLA ZOSTER VIRUS INFECTION |
2 |
0.0010 |
| 53 |
NON-CARDIOGENIC PULMONARY OEDEMA |
1 |
0.0009 |
| 54 |
CATHETER SITE DISCHARGE |
1 |
0.0009 |
| 55 |
DISTRIBUTIVE SHOCK |
2 |
0.0009 |
| 56 |
IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME |
5 |
0.0008 |
| 57 |
FULL BLOOD COUNT INCREASED |
1 |
0.0008 |
| 58 |
HYPERNATRAEMIA |
4 |
0.0008 |
| 59 |
CARDIAC VENTRICULAR THROMBOSIS |
1 |
0.0008 |
| 60 |
VIRAL LOAD INCREASED |
3 |
0.0008 |
| 61 |
EPSTEIN-BARR VIRUS INFECTION REACTIVATION |
1 |
0.0008 |
| 62 |
MYOPATHY |
6 |
0.0007 |
| 63 |
BRAIN HERNIATION |
2 |
0.0007 |
| 64 |
STEROID DIABETES |
1 |
0.0007 |
| 65 |
HAEMODYNAMIC INSTABILITY |
5 |
0.0007 |
| 66 |
LOSS OF THERAPEUTIC RESPONSE |
2 |
0.0006 |
| 67 |
SPLENIC RUPTURE |
1 |
0.0006 |
| 68 |
PUPIL FIXED |
1 |
0.0006 |
| 69 |
EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER |
1 |
0.0006 |
| 70 |
HAEMORRHAGIC DIATHESIS |
2 |
0.0006 |
| 71 |
HYPERTRIGLYCERIDAEMIA |
3 |
0.0005 |
| 72 |
DISSEMINATED INTRAVASCULAR COAGULATION |
7 |
0.0005 |
| 73 |
MULTIPLE ORGAN DYSFUNCTION SYNDROME |
14 |
0.0005 |
| 74 |
SEPTIC SHOCK |
21 |
0.0005 |
| 75 |
RED CELL DISTRIBUTION WIDTH INCREASED |
2 |
0.0005 |
| 76 |
ACUTE MYELOID LEUKAEMIA RECURRENT |
1 |
0.0005 |
| 77 |
STAPHYLOCOCCAL BACTERAEMIA |
2 |
0.0005 |
| 78 |
CYTOMEGALOVIRUS INFECTION REACTIVATION |
2 |
0.0005 |
| 79 |
IMPLANT SITE INFECTION |
1 |
0.0004 |
| 80 |
ESCHERICHIA BACTERAEMIA |
1 |
0.0004 |
| 81 |
GRAFT VERSUS HOST DISEASE |
3 |
0.0004 |
| 82 |
ENTEROCOCCAL INFECTION |
2 |
0.0004 |
| 83 |
CYTOPENIA |
5 |
0.0004 |
| 84 |
STAPHYLOCOCCAL SEPSIS |
2 |
0.0004 |
| 85 |
BLOOD IMMUNOGLOBULIN G DECREASED |
1 |
0.0004 |
| 86 |
SYSTEMIC CANDIDA |
1 |
0.0004 |
| 87 |
PLATELET DISORDER |
1 |
0.0004 |
| 88 |
DERMATOMYOSITIS |
1 |
0.0004 |
| 89 |
MEAN CELL VOLUME INCREASED |
1 |
0.0004 |
| 90 |
GENERALISED TONIC-CLONIC SEIZURE |
6 |
0.0004 |
| 91 |
LYMPHOPROLIFERATIVE DISORDER |
1 |
0.0003 |
| 92 |
PULMONARY HYPERTENSION |
7 |
0.0003 |
| 93 |
EMBOLISM VENOUS |
1 |
0.0003 |
| 94 |
HEPATIC CIRRHOSIS |
6 |
0.0003 |
| 95 |
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME |
3 |
0.0003 |
| 96 |
SUSPECTED COVID-19 |
1 |
0.0003 |
| 97 |
HYPERBILIRUBINAEMIA |
3 |
0.0003 |
| 98 |
FIBRIN D DIMER INCREASED |
1 |
0.0003 |
| 99 |
LOWER GASTROINTESTINAL HAEMORRHAGE |
2 |
0.0003 |
| 100 |
NERVOUS SYSTEM DISORDER |
8 |
0.0003 |
| 101 |
HAEMORRHAGIC STROKE |
2 |
0.0003 |
| 102 |
PNEUMONIA FUNGAL |
1 |
0.0003 |
| 103 |
BACTERAEMIA |
3 |
0.0003 |
| 104 |
ORGAN FAILURE |
1 |
0.0002 |
| 105 |
GASTROINTESTINAL PERFORATION |
1 |
0.0002 |
| 106 |
LEFT VENTRICULAR HYPERTROPHY |
1 |
0.0002 |
| 107 |
SUSPECTED OFF LABEL USE |
1 |
0.0002 |
| 108 |
HYPERGLYCAEMIA |
8 |
0.0002 |
| 109 |
DISEASE COMPLICATION |
1 |
0.0002 |
| 110 |
CYTOKINE RELEASE SYNDROME |
4 |
0.0002 |
| 111 |
KLEBSIELLA INFECTION |
1 |
0.0002 |
| 112 |
CONDITION AGGRAVATED |
60 |
0.0002 |
| 113 |
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER |
1 |
0.0002 |
| 114 |
APLASTIC ANAEMIA |
1 |
0.0002 |
| 115 |
COLITIS |
7 |
0.0002 |
| 116 |
CYTOMEGALOVIRUS INFECTION |
3 |
0.0002 |
| 117 |
HYPERTENSIVE CRISIS |
2 |
0.0002 |
| 118 |
STREPTOCOCCAL INFECTION |
1 |
0.0002 |
| 119 |
PULMONARY ALVEOLAR HAEMORRHAGE |
1 |
0.0002 |
| 120 |
CANDIDA INFECTION |
3 |
0.0002 |
| 121 |
LYMPHOCYTE COUNT DECREASED |
3 |
0.0002 |
| 122 |
CHOLANGITIS |
1 |
0.0002 |
| 123 |
WHITE BLOOD CELL COUNT ABNORMAL |
1 |
0.0002 |
| 124 |
HEPATITIS |
4 |
0.0002 |
| 125 |
DRUG RESISTANCE |
4 |
0.0002 |
| 126 |
HAEMOGLOBIN ABNORMAL |
1 |
0.0002 |
| 127 |
HYPOGAMMAGLOBULINAEMIA |
1 |
0.0002 |
| 128 |
IMMUNE SYSTEM DISORDER |
2 |
0.0002 |
| 129 |
BONE MARROW FAILURE |
3 |
0.0001 |
| 130 |
GENERAL PHYSICAL CONDITION ABNORMAL |
1 |
0.0001 |
| 131 |
BODY TEMPERATURE INCREASED |
3 |
0.0001 |
| 132 |
PRODUCT AVAILABILITY ISSUE |
3 |
0.0001 |
| 133 |
DEVICE RELATED INFECTION |
2 |
0.0001 |
| 134 |
PULMONARY HAEMORRHAGE |
1 |
0.0001 |
| 135 |
RESPIRATORY FAILURE |
9 |
0.0001 |
| 136 |
ENCEPHALOPATHY |
3 |
0.0001 |
| 137 |
HAEMOLYTIC ANAEMIA |
1 |
0.0001 |
| 138 |
PRODUCT DISTRIBUTION ISSUE |
1 |
0.0001 |
| 139 |
OFF LABEL USE |
94 |
0.0001 |
| 140 |
FULL BLOOD COUNT ABNORMAL |
1 |
0.0001 |
| 141 |
CLOSTRIDIUM DIFFICILE COLITIS |
1 |
0.0001 |
| 142 |
DECREASED ACTIVITY |
1 |
0.0001 |
| 143 |
INTESTINAL PERFORATION |
1 |
0.0001 |
| 144 |
STATUS EPILEPTICUS |
1 |
0.0001 |
| 145 |
SPLENOMEGALY |
1 |
0.0001 |
| 146 |
GASTROINTESTINAL HAEMORRHAGE |
7 |
0.0001 |
| 147 |
SEPSIS |
9 |
0.0001 |
| 148 |
HEPATIC CYTOLYSIS |
1 |
0.0001 |
| 149 |
BEDRIDDEN |
1 |
0.0001 |
| 150 |
SARS-COV-2 TEST POSITIVE |
1 |
0.0001 |
| 151 |
OEDEMA |
4 |
0.0001 |
| 152 |
TACHYPNOEA |
1 |
0.0001 |
| 153 |
BLOOD TEST ABNORMAL |
1 |
0.0001 |
| 154 |
SUBDURAL HAEMATOMA |
1 |
0.0001 |
| 155 |
CARDIOGENIC SHOCK |
1 |
0.0001 |
| 156 |
COMPLICATION ASSOCIATED WITH DEVICE |
1 |
0.0001 |
| 157 |
LIVER FUNCTION TEST ABNORMAL |
2 |
0.0001 |
| 158 |
IMMUNODEFICIENCY |
1 |
0.0001 |
| 159 |
HAEMORRHAGE INTRACRANIAL |
1 |
0.0001 |
| 160 |
PLATELET COUNT DECREASED |
7 |
0.0001 |
| 161 |
LYMPHOMA |
1 |
0.0001 |
| 162 |
MUSCULOSKELETAL CHEST PAIN |
1 |
0.0001 |
| 163 |
ACUTE MYELOID LEUKAEMIA |
1 |
0.0001 |
| 164 |
THROMBOCYTOPENIA |
7 |
0.0001 |
| 165 |
HYPERTENSION |
13 |
0.0001 |
| 166 |
FUNGAL INFECTION |
2 |
0.0001 |
| 167 |
FACE OEDEMA |
1 |
0.0001 |
| 168 |
HYPOXIA |
2 |
0.0001 |
| 169 |
PANCREATITIS |
3 |
0.0001 |
| 170 |
ACUTE RESPIRATORY DISTRESS SYNDROME |
1 |
0.0001 |
| 171 |
SYSTEMIC LUPUS ERYTHEMATOSUS |
2 |
0.0001 |
| 172 |
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION |
3 |
0.0001 |
| 173 |
PROTEINURIA |
1 |
0.0001 |
| 174 |
PULMONARY FIBROSIS |
1 |
0.0001 |
| 175 |
ACUTE RESPIRATORY FAILURE |
1 |
0.0001 |
| 176 |
SEIZURE |
6 |
0.0001 |
| 177 |
NEUTROPHIL COUNT DECREASED |
2 |
0.0000 |
| 178 |
CARDIAC ARREST |
4 |
0.0000 |
| 179 |
CARDIO-RESPIRATORY ARREST |
2 |
0.0000 |
| 180 |
LIVER FUNCTION TEST INCREASED |
1 |
0.0000 |
| 181 |
GAMMA-GLUTAMYLTRANSFERASE INCREASED |
1 |
0.0000 |
| 182 |
RASH MACULO-PAPULAR |
1 |
0.0000 |
| 183 |
THERAPY NON-RESPONDER |
2 |
0.0000 |
| 184 |
PANCREATITIS ACUTE |
1 |
0.0000 |
| 185 |
CHILLS |
5 |
0.0000 |
| 186 |
DISEASE PROGRESSION |
5 |
0.0000 |
| 187 |
PRESYNCOPE |
1 |
0.0000 |
| 188 |
HYPOTENSION |
8 |
0.0000 |
| 189 |
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS |
1 |
0.0000 |
| 190 |
PYREXIA |
13 |
0.0000 |
| 191 |
RESPIRATORY DISTRESS |
1 |
0.0000 |
| 192 |
HERPES ZOSTER |
2 |
0.0000 |
| 193 |
LABORATORY TEST ABNORMAL |
1 |
0.0000 |
| 194 |
DEATH |
29 |
0.0000 |
| 195 |
IRRITABILITY |
2 |
0.0000 |
| 196 |
HEPATIC FAILURE |
1 |
0.0000 |
| 197 |
LIMB DISCOMFORT |
1 |
0.0000 |
| 198 |
EXPOSURE DURING PREGNANCY |
2 |
0.0000 |
| 199 |
LACTIC ACIDOSIS |
1 |
0.0000 |
| 200 |
LIP SWELLING |
1 |
0.0000 |
| 201 |
SKIN DISORDER |
1 |
0.0000 |
| 202 |
HEPATIC ENZYME INCREASED |
2 |
0.0000 |
| 203 |
HAEMOGLOBIN DECREASED |
3 |
0.0000 |
| 204 |
LYMPHADENOPATHY |
1 |
0.0000 |
| 205 |
THERAPEUTIC PRODUCT EFFECT INCOMPLETE |
2 |
0.0000 |
| 206 |
INFECTION |
4 |
0.0000 |
| 207 |
CRYING |
1 |
0.0000 |
| 208 |
DYSURIA |
1 |
0.0000 |
| 209 |
DRUG INEFFECTIVE |
32 |
0.0000 |
| 210 |
TREATMENT FAILURE |
2 |
0.0000 |
| 211 |
INTENTIONAL PRODUCT MISUSE |
2 |
0.0000 |
| 212 |
INTENTIONAL PRODUCT USE ISSUE |
2 |
0.0000 |
| 213 |
PULMONARY OEDEMA |
1 |
0.0000 |
| 214 |
LOWER RESPIRATORY TRACT INFECTION |
1 |
0.0000 |
| 215 |
HYPOKALAEMIA |
1 |
0.0000 |
| 216 |
INFLAMMATION |
1 |
0.0000 |
| 217 |
ASPARTATE AMINOTRANSFERASE INCREASED |
1 |
0.0000 |
| 218 |
WHITE BLOOD CELL COUNT DECREASED |
2 |
0.0000 |
| 219 |
ANAPHYLACTIC REACTION |
1 |
0.0000 |
| 220 |
PANCYTOPENIA |
1 |
0.0000 |
| 221 |
BLISTER |
1 |
0.0000 |
| 222 |
HYPONATRAEMIA |
1 |
0.0000 |
| 223 |
GENERAL PHYSICAL HEALTH DETERIORATION |
2 |
0.0000 |
| 224 |
ABDOMINAL PAIN |
4 |
0.0000 |
| 225 |
PRODUCT DOSE OMISSION ISSUE |
5 |
0.0000 |
| 226 |
CATARACT |
1 |
0.0000 |
| 227 |
THERAPEUTIC RESPONSE DECREASED |
1 |
0.0000 |
| 228 |
VERTIGO |
1 |
0.0000 |
| 229 |
ALANINE AMINOTRANSFERASE INCREASED |
1 |
0.0000 |
| 230 |
NEOPLASM MALIGNANT |
1 |
0.0000 |
| 231 |
ARTHRITIS |
1 |
0.0000 |
| 232 |
CARDIAC FAILURE CONGESTIVE |
1 |
0.0000 |
| 233 |
CONFUSIONAL STATE |
2 |
0.0000 |
| 234 |
TOXICITY TO VARIOUS AGENTS |
2 |
0.0000 |
| 235 |
BALANCE DISORDER |
1 |
0.0000 |
| 236 |
RASH |
5 |
0.0000 |
| 237 |
TACHYCARDIA |
1 |
0.0000 |
| 238 |
DEVICE ISSUE |
1 |
0.0000 |
| 239 |
CHEST PAIN |
2 |
0.0000 |
| 240 |
VOMITING |
5 |
0.0000 |
| 241 |
PULMONARY EMBOLISM |
1 |
0.0000 |
| 242 |
NEUROPATHY PERIPHERAL |
1 |
0.0000 |
| 243 |
ANAEMIA |
2 |
0.0000 |
| 244 |
FLUSHING |
1 |
0.0000 |
| 245 |
ILLNESS |
1 |
0.0000 |
| 246 |
INFLUENZA |
1 |
0.0000 |
| 247 |
WEIGHT INCREASED |
2 |
0.0000 |
| 248 |
FEELING ABNORMAL |
2 |
0.0000 |
| 249 |
VISUAL IMPAIRMENT |
1 |
0.0000 |
| 250 |
LOSS OF CONSCIOUSNESS |
1 |
0.0000 |
| 251 |
HYPERHIDROSIS |
1 |
0.0000 |
| 252 |
RENAL FAILURE |
1 |
0.0000 |
| 253 |
NEUTROPENIA |
1 |
0.0000 |
| 254 |
ACUTE KIDNEY INJURY |
1 |
0.0000 |
| 255 |
PARAESTHESIA |
1 |
0.0000 |
| 256 |
URINARY TRACT INFECTION |
1 |
0.0000 |
| 257 |
COVID-19 |
1 |
0.0000 |
| 258 |
NO ADVERSE EVENT |
1 |
0.0000 |
| 259 |
NAUSEA |
4 |
0.0000 |
| 260 |
SOMNOLENCE |
1 |
0.0000 |
| 261 |
CONSTIPATION |
1 |
0.0000 |
| 262 |
PRODUCT USE IN UNAPPROVED INDICATION |
1 |
0.0000 |
| 263 |
PAIN IN EXTREMITY |
1 |
0.0000 |
| 264 |
PNEUMONIA |
1 |
0.0000 |
| 265 |
ARTHRALGIA |
1 |
0.0000 |
| 266 |
MALAISE |
1 |
0.0000 |
| 267 |
DYSPNOEA |
1 |
0.0000 |
| 268 |
PAIN |
1 |
0.0000 |
| 269 |
HEADACHE |
1 |
0.0000 |